BACKGROUND: Human atherosclerotic lesions contain elevated levels of urokinase plasminogen activator (uPA), expressed predominantly by macrophages. METHODS AND RESULTS: To test the hypothesis that macrophage-expressed uPA contributes to the progression and complications of atherosclerosis, we generated transgenic mice with macrophage-targeted overexpression of uPA. The uPA transgene was bred into the apolipoprotein E-null background, and transgenic mice and nontransgenic littermate controls were fed an atherogenic diet. uPA-transgenic mice had significantly elevated uPA activity in the atherosclerotic artery wall, of a magnitude similar to elevations reported in atherosclerotic human arteries. Compared with littermate controls, uPA-transgenic mice had accelerated atherosclerosis, dilated aortic roots, occlusive proximal coronary artery disease, myocardial infarcts, and early mortality. CONCLUSIONS: These data support the hypothesis that overexpression of uPA by artery wall macrophages is atherogenic and suggest that uPA inhibitors might be therapeutically useful.
BACKGROUND:Humanatherosclerotic lesions contain elevated levels of urokinase plasminogen activator (uPA), expressed predominantly by macrophages. METHODS AND RESULTS: To test the hypothesis that macrophage-expressed uPA contributes to the progression and complications of atherosclerosis, we generated transgenic mice with macrophage-targeted overexpression of uPA. The uPA transgene was bred into the apolipoprotein E-null background, and transgenic mice and nontransgenic littermate controls were fed an atherogenic diet. uPA-transgenic mice had significantly elevated uPA activity in the atherosclerotic artery wall, of a magnitude similar to elevations reported in atherosclerotichuman arteries. Compared with littermate controls, uPA-transgenic mice had accelerated atherosclerosis, dilated aortic roots, occlusive proximal coronary artery disease, myocardial infarcts, and early mortality. CONCLUSIONS: These data support the hypothesis that overexpression of uPA by artery wall macrophages is atherogenic and suggest that uPA inhibitors might be therapeutically useful.
Authors: Jie Hong Hu; Liang Du; Talyn Chu; Goro Otsuka; Nagadhara Dronadula; Mia Jaffe; Sean E Gill; William C Parks; David A Dichek Journal: Circulation Date: 2010-03-29 Impact factor: 29.690
Authors: Elina Minami; Chiara Castellani; Laura Malchodi; Jennifer Deem; Kate Bertko; Jessica Meznarich; Monja Dishmon; Charles E Murry; April Stempien-Otero Journal: J Mol Cell Cardiol Date: 2010-04-07 Impact factor: 5.000
Authors: Margaret L Novak; Scott C Bryer; Ming Cheng; Mai-Huong Nguyen; Kevin L Conley; Andrew K Cunningham; Bing Xue; Thomas H Sisson; Jae-Sung You; Troy A Hornberger; Timothy J Koh Journal: J Immunol Date: 2011-06-27 Impact factor: 5.422
Authors: Michal Kremen; Ranjini Krishnan; Isaac Emery; Jie Hong Hu; Katherine I Slezicki; Alyssa Wu; Kun Qian; Liang Du; Abigail Plawman; April Stempien-Otero; David A Dichek Journal: Proc Natl Acad Sci U S A Date: 2008-10-28 Impact factor: 11.205
Authors: Paraskevi Briassouli; Marc K Halushka; Joanne H Reed; Yair Molad; Karen Fox-Talbot; Lucas Buyon; Edwin Guzman; Achiau Ludomirsky; Robert M Clancy; Jill P Buyon Journal: Rheumatology (Oxford) Date: 2013-04-18 Impact factor: 7.580
Authors: Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay Journal: Arterioscler Thromb Vasc Biol Date: 2020-04-09 Impact factor: 8.311
Authors: Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith Journal: J Vasc Surg Date: 2009-08-22 Impact factor: 4.268